These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

254 related items for PubMed ID: 28734858

  • 1. Safety Review of 5-Grass Pollen Tablet from Pooled Data of Clinical Trials.
    Casale TB, Cox LS, Wahn U, Golden DBK, Bons B, Didier A.
    J Allergy Clin Immunol Pract; 2017; 5(6):1717-1727.e1. PubMed ID: 28734858
    [Abstract] [Full Text] [Related]

  • 2. Real-life safety of 5-grass pollen tablet in 5-to-9-year-old children with allergic rhinoconjunctivitis.
    Gerstlauer M, Szepfalusi Z, Golden D, Geng B, de Blic J.
    Ann Allergy Asthma Immunol; 2019 Jul; 123(1):70-80. PubMed ID: 31009701
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Immunologic effects and tolerability profile of in-season initiation of a standardized-quality grass allergy immunotherapy tablet: a phase III, multicenter, randomized, double-blind, placebo-controlled trial in adults with grass pollen-induced rhinoconjunctivitis.
    Reich K, Gessner C, Kroker A, Schwab JA, Pohl W, Villesen H, Wüstenberg E, Emminger W.
    Clin Ther; 2011 Jul; 33(7):828-40. PubMed ID: 21741092
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Epinephrine Use in Clinical Trials of Sublingual Immunotherapy Tablets.
    Nolte H, Casale TB, Lockey RF, Fogh BS, Kaur A, Lu S, Nelson HS.
    J Allergy Clin Immunol Pract; 2017 Jul; 5(1):84-89.e3. PubMed ID: 27838323
    [Abstract] [Full Text] [Related]

  • 9. Dose-finding study of carbamylated monomeric allergoid tablets in grass-allergic rhinoconjunctivitis patients.
    Mösges R, Rohdenburg C, Eichel A, Zadoyan G, Kasche EM, Shah-Hosseini K, Lehmacher W, Schmalz P, Compalati E.
    Immunotherapy; 2017 Nov; 9(15):1225-1238. PubMed ID: 29130797
    [Abstract] [Full Text] [Related]

  • 10. Efficacy and safety of 5-grass pollen sublingual immunotherapy tablets in patients with different clinical profiles of allergic rhinoconjunctivitis.
    Malling HJ, Montagut A, Melac M, Patriarca G, Panzner P, Seberova E, Didier A.
    Clin Exp Allergy; 2009 Mar; 39(3):387-93. PubMed ID: 19134019
    [Abstract] [Full Text] [Related]

  • 11. Sublingual Immunotherapy with a Five-Grass Pollen Tablet in Adult Patients with Allergic Rhinitis: An Open, Prospective, Noninterventional, Multicenter Study.
    Pfaar O, Richter HG, Klimek L, Sieber J, Hadler M, Karagiannis E.
    Biomed Res Int; 2015 Mar; 2015():584291. PubMed ID: 26351635
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Safety of sublingual immunotherapy Timothy grass tablet in subjects with allergic rhinitis with or without conjunctivitis and history of asthma.
    Maloney J, Durham S, Skoner D, Dahl R, Bufe A, Bernstein D, Murphy K, Waserman S, Berman G, White M, Kaur A, Nolte H.
    Allergy; 2015 Mar; 70(3):302-9. PubMed ID: 25495666
    [Abstract] [Full Text] [Related]

  • 14. Safety of a SQ-standardised grass allergen tablet for sublingual immunotherapy: a randomized, placebo-controlled trial.
    Kleine-Tebbe J, Ribel M, Herold DA.
    Allergy; 2006 Feb; 61(2):181-4. PubMed ID: 16409193
    [Abstract] [Full Text] [Related]

  • 15. An observational, real-life safety study of a 5-grass pollen sublingual tablet in children and adolescents.
    Eberle P, Brueck H, Gall R, Hadler M, Sieber J, Karagiannis E.
    Pediatr Allergy Immunol; 2014 Dec; 25(8):760-6. PubMed ID: 25378225
    [Abstract] [Full Text] [Related]

  • 16. Efficacy and safety of grass sublingual immunotherapy tablet, MK-7243: a large randomized controlled trial.
    Maloney J, Bernstein DI, Nelson H, Creticos P, Hébert J, Noonan M, Skoner D, Zhou Y, Kaur A, Nolte H.
    Ann Allergy Asthma Immunol; 2014 Feb; 112(2):146-153.e2. PubMed ID: 24468255
    [Abstract] [Full Text] [Related]

  • 17. Treatment with grass allergen peptides improves symptoms of grass pollen-induced allergic rhinoconjunctivitis.
    Ellis AK, Frankish CW, O'Hehir RE, Armstrong K, Steacy L, Larché M, Hafner RP.
    J Allergy Clin Immunol; 2017 Aug; 140(2):486-496. PubMed ID: 28236469
    [Abstract] [Full Text] [Related]

  • 18. Grass pollen sublingual immunotherapy tablets provide long-term relief of grass pollen-associated allergic rhinitis and reduce the risk of asthma: findings from a retrospective, real-world database subanalysis.
    Devillier P, Wahn U, Zielen S, Heinrich J.
    Expert Rev Clin Immunol; 2017 Dec; 13(12):1199-1206. PubMed ID: 29072507
    [Abstract] [Full Text] [Related]

  • 19. Specific immunotherapy with SQ standardized grass allergen tablets in asthmatics with rhinoconjunctivitis.
    Dahl R, Stender A, Rak S.
    Allergy; 2006 Feb; 61(2):185-90. PubMed ID: 16409194
    [Abstract] [Full Text] [Related]

  • 20. Five-grass-pollen sublingual immunotherapy tablet for the treatment of grass-pollen-induced allergic rhinoconjunctivitis: 5 years of experience.
    Didier A, Wahn U, Horak F, Cox LS.
    Expert Rev Clin Immunol; 2014 Oct; 10(10):1309-24. PubMed ID: 25205329
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.